No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	nivolumab + IPI-549 Sensitive: B - Late Trials nivolumab + IPI-549 Sensitive : B	nivolumab + IPI-549 Sensitive: B - Late Trials nivolumab + IPI-549 Sensitive : B
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	IPI-549 Sensitive: B - Late Trials IPI-549 Sensitive : B	IPI-549 Sensitive: B - Late Trials IPI-549 Sensitive : B
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive: C2 – Inclusion Criteria bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive : C2	bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive: C2 – Inclusion Criteria bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive : C2
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	bevacizumab + atezolizumab + IPI-549 Sensitive: C2 – Inclusion Criteria bevacizumab + atezolizumab + IPI-549 Sensitive : C2	bevacizumab + atezolizumab + IPI-549 Sensitive: C2 – Inclusion Criteria bevacizumab + atezolizumab + IPI-549 Sensitive : C2
CXCL11 elevation	Follicular Lymphoma	CXCL11 elevation	Follicular Lymphoma	duvelisib Resistant: C3 – Early Trials duvelisib Resistant : C3	duvelisib Resistant: C3 – Early Trials duvelisib Resistant : C3
IL2RA elevation	Follicular Lymphoma	IL2RA elevation	Follicular Lymphoma	duvelisib Resistant: C3 – Early Trials duvelisib Resistant : C3	duvelisib Resistant: C3 – Early Trials duvelisib Resistant : C3
Chr del(6q)(q15)	Follicular Lymphoma	Chr del(6q)(q15)	Follicular Lymphoma	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3
PD-L1 underexpression	Urothelial Cancer	PD-L1 underexpression	Urothelial Cancer	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3
PD-L1 negative	Urothelial Cancer	PD-L1 negative	Urothelial Cancer	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + duvelisib Sensitive: C3 – Early Trials venetoclax + duvelisib Sensitive : C3	venetoclax + duvelisib Sensitive: C3 – Early Trials venetoclax + duvelisib Sensitive : C3
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + duvelisib Sensitive: C3 – Early Trials venetoclax + duvelisib Sensitive : C3	venetoclax + duvelisib Sensitive: C3 – Early Trials venetoclax + duvelisib Sensitive : C3
PIK3CD expression	Squamous Cell Carcinoma of Head and Neck	PIK3CD expression	Squamous Cell Carcinoma of Head and Neck	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CG expression	Squamous Cell Carcinoma of Head and Neck	PIK3CG expression	Squamous Cell Carcinoma of Head and Neck	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CG overexpression	Squamous Cell Carcinoma of Head and Neck	PIK3CG overexpression	Squamous Cell Carcinoma of Head and Neck	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CD overexpression	Squamous Cell Carcinoma of Head and Neck	PIK3CD overexpression	Squamous Cell Carcinoma of Head and Neck	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CG overexpression	Melanoma	PIK3CG overexpression	Melanoma	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D

PI3Kγ inhibitor

PI3Kγ inhibitor

Associations(41)

Associations
(41)